Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535920 · ClinicalTrials.gov registry record · Phase 4
A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia
A Phase 4 study, sponsored by NephroNet.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
NCT05535920 is a Phase 4 study that has completed, run by NephroNet. The registered enrollment target is 88 participants.
The verdict
NCT05535920, a Phase 4 study, has completed, sponsored by NephroNet.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
Study Summary
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial
Interventions
- DRUG LOKELMA 5 GM Powder for Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05535920
The ClinicalTrials.gov registry entry for NCT05535920 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NephroNet, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LOKELMA 5 GM Powder for Oral Suspension is the first listed.
NCT05535920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05535920 about?
NCT05535920 is a clinical study titled "A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia". A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhyt...
What is the current status of trial NCT05535920?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2022-04-14. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT05535920?
The interventions under investigation include: LOKELMA 5 GM Powder for Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT05535920?
This trial is sponsored by NephroNet, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.